Market & Company News

Overview Saudi Aramco reported solid Q2 2025 results, underpinned by stable operational performance and disciplined cost control, despite lower average oil prices and reduced production volumes. President & CEO Amin H. Nasser highlighted the company’s strategic focus on maximizing downstream value, expanding global partnerships, and maintaining capital discipline while progressing toward energy transition objectives: “Aramco’s…

Overview AMD delivered a strong Q2 2025 performance, with a 32% year-over-year increase in revenue, supported by robust demand across Data Center and Client segments. However, profitability was impacted by inventory charges related to new U.S. export controls affecting Instinct MI308 shipments. CEO Dr. Lisa Su stated: “We delivered strong revenue growth in the second…

Overview Qualcomm delivered a strong Q3 FY2025 performance, driven by continued growth in automotive and IoT, as well as sustained demand in handset markets. The company highlighted its leadership in AI processing, energy-efficient computing, and advanced connectivity, which are central to its long-term diversification strategy. “Another quarter of strong growth in QCT Automotive and IoT…

Overview Ferrari delivered strong financial results in the second quarter of 2025, driven by an enriched product mix, higher personalizations, and strong brand performance, despite essentially flat shipments. “The first semester of 2025 reminded us once more about the importance of agility and flexibility in the management of our Company. Today’s strong results reflect our…

Overview Booking Holdings delivered a strong second quarter of 2025, reflecting the ongoing recovery and growth in global travel demand. The company achieved double-digit revenue and profit growth, supported by robust room nights, expanding alternative accommodations, and continued momentum in flights and attractions. CEO Glenn Fogel highlighted: “I am pleased to report a strong quarter…

Overview Merck & Co., Inc. delivered solid operational performance in Q2 2025 despite a slight decline in total revenue, reflecting robust oncology and cardiovascular growth offset by weaker vaccine sales. The company continued to advance its strategy with a focus on pipeline expansion and high-value acquisitions, including Verona Pharma, while initiating a multiyear optimization program…

Overview Linde delivered another quarter of resilient performance in Q2 2025, driven by pricing actions, operational efficiency, and a focus on high-return projects. Despite softer volumes in certain industrial and manufacturing markets, the company achieved revenue growth, margin expansion, and robust cash generation. Management highlighted the continued execution of its high-quality project backlog and reaffirmed…

Overview Palantir achieved a record-breaking Q2 2025, fueled by explosive growth in U.S. commercial operations and accelerating global adoption of its AI Platform (AIP). The company raised its full-year revenue guidance to +45% YoY, surpassing consensus expectations. CEO Alex Karp highlighted that the company’s U.S. commercial revenue nearly doubled, reflecting rapid enterprise adoption and deepening…

Overview Strategy (MicroStrategy) posted record Q2 2025 results, driven by the fair value appreciation of its substantial Bitcoin holdings and aggressive capital markets activity. Earnings reached historic highs, reflecting both Bitcoin price momentum and disciplined accretive capital deployment. CEO Phong Le highlighted the company’s leadership as the world’s first Bitcoin Treasury Company, with accelerating institutional…

Overview Starbucks posted Q3 FY2025 results showing modest revenue growth but significant margin contraction, reflecting ongoing investments in its “Back to Starbucks” strategy. EPS was negatively impacted by one-time investments in Leadership Experience 2025 and discrete tax adjustments. CEO Brian Niccol emphasized the progress in rebuilding operational foundations and preparing for 2026 innovation, with a…

Overview UnitedHealth Group reported Q2 2025 results reflecting strong top-line growth but significant margin pressure from higher-than-anticipated medical costs. The company re-established its full-year 2025 outlook, incorporating revised expectations for medical cost trends and Medicare funding impacts. CEO Stephen Hemsley emphasized the company’s focus on restoring operating discipline and preparing for earnings recovery in 2026:…

Overview AbbVie delivered strong operational performance in the second quarter of 2025, supported by double-digit growth in Immunology and Neuroscience. Net revenues increased to $15.42bn, reflecting portfolio expansion and continued demand for key growth products. CEO Richard Gonzalez emphasized that AbbVie’s diversified portfolio and advancing pipeline position the company for sustainable long-term growth despite ongoing…